Renal Denervation Market Report, published by Allied Market Research, forecasts that the global market was valued at $197 million in 2015, and is expected to reach $3,153 million by 2022, supported by a CAGR of 48.5% during the forecast period 2014 – 2022. Symplicity Renal Denervation System is estimated to continue generating highest revenue throughout the forecast period, owing to growing number of product approvals across the globe. Europe held the leading position in the global market in 2015, and is expected to maintain its lead in the future.
Increasing prevalence and incidence of hypertension and blood pressure, changing lifestyle of the people, improvement of healthcare infrastructure in developing countries, and cost effectiveness of the renal denervation procedure as compared to other multidrug treatment therapies propel the market growth. However, stringent approval process for renal denervation devices, and patient discomfort and pain that arises during the procedure hamper the market growth.
To Remain ‘Ahead’ Of Your Competitors, Request For A Sample @ https://www.alliedmarketresearch.com/request-sample/522
COVID-19 scenario analysis:
1) The COVID-19 impact on the Renal denervation market is unpredictable and is expected to remain in force till the fourth quarter of 2021.
2) The COVID-19 outbreak forced governments across the globe to implement strict lockdowns and banned import-export of nonessential items for most of 2021. This led to sudden fall in the availability of important raw materials.
3) Moreover, nationwide lockdowns forced manufacturing facilities to partially or completely shut their operations.
4) Adverse impacts of the COVID-19 pandemic have resulted in delays in activities and initiatives regarding development of reliable and innovative drone analytics systems globally.
Inquiry for Short-term and Long-term Impacts of COVID-19 at: https://www.alliedmarketresearch.com/request-for-customization/522?reqfor=covid
Key findings of Renal Denervation Market:
•On the basis of product type, the Symplicity Renal Denervation System segment accounted for the largest share, while Vessix Renal Denervation System is projected to grow at the fastest rate.
•Radiofrequency segment dominated the overall renal denervation market.
•Utrasound is poised to grow at the highest CAGR of 56.4% during the analysis period.
•Europe was the leading geographic market in 2015, and it is projected to lead for the next few years.
•Asia-Pacific is projected to grow at the highest CAGR of 50.6%.
Europes high share is attributed to the early start of this technology in European countries. In addition, most of the devices in this market have received a CE mark approval and are available for sales in the European region. On the other hand, North America accounts for a small proportion as renal denervation systems have not been approved by the FDA and are available only for investigational purpose in the North American market.
List of Key Players Profiled in the Report: